-

Exo Receives $11.6 Million Grant to Expand Access to AI-Powered Ultrasound

The funding will advance Exo’s silicon and AI platform to bring affordable, real-time imaging to frontline workers, with support from the Gates Foundation.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Exo (pronounced “echo”) today announced an $11.6 million grant from the Gates Foundation to advance its next-generation technology and expand access to essential diagnostic imaging in low- and middle-income countries.

By combining silicon imaging with on-device AI, Exo is working to make ultrasound more affordable and easier for frontline healthcare workers to use.

Share

The funding will support development of an affordable, multi-use handheld ultrasound system that enables frontline healthcare workers without specialized ultrasound expertise to acquire and interpret images for essential diagnostics and risk screening.

The Exo platform integrates advanced silicon-based imaging hardware with AI that guides image acquisition and interpretation in real time. The AI runs directly on the device, without requiring an internet connection. The technology is designed to address key barriers to ultrasound access, including equipment costs, imaging complexity, specialist shortages, and unreliable connectivity.

“By combining silicon imaging with on-device AI, we’re working to make ultrasound more affordable and easier for frontline healthcare workers to use,” said Sandeep Akkaraju, CEO of Exo. “This funding will help us advance a platform designed for communities where access to imaging and specialist expertise is limited. We’re grateful to the Gates Foundation for its continued support.”

The grant-funded work draws on the same silicon and AI platform Exo is developing for handheld ultrasound and OEM-integrated systems, with applications across diagnostic imaging, procedure guidance, therapy, and monitoring.

About Exo

Exo is redefining medical imaging with its advanced ultrasound platform, combining piezoelectric silicon hardware with tightly integrated AI. The platform enables compact, high-performance systems for diagnostic imaging, procedure guidance, and emerging therapeutic applications, expanding access to medical imaging across diverse care settings.

For more information, visit www.exo.inc.

Follow us at @exoeffect on X, LinkedIn, Facebook, and Instagram.

Contacts

For media inquiries: media@exo.inc.

More News From Exo

Exo Removes the Subscription Barrier for Handheld Ultrasound

SANTA CLARA, Calif.--(BUSINESS WIRE)--Exo (pronounced “echo”), the leader in AI-powered, accessible medical imaging, today announced expanded deployment options for Exo Iris® that give healthcare providers the freedom to choose the handheld ultrasound experience that best fits their clinical setting, infrastructure, and scale. The options extend Exo Iris from large, connected imaging programs to single operators and care teams working in disconnected environments. The expansion removes a key ad...

Exo Launches a New Era in Disease Diagnosis with the First FDA-cleared Ultrasound AI for Detection of Pleural Effusion and Consolidation/Atelectasis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Exo (pronounced “echo”), the leader in AI-powered, accessible medical imaging, is transforming lung disease diagnosis with another first. Now included on Exo Iris® is the first ever FDA 510(k) cleared AI for detecting pleural effusion and consolidation/atelectasis. These on-device real-time indicators empower clinicians with objective data to help detect lung diseases like pneumonia and tuberculosis at the bedside in seconds. Arun Nagdev, MD, Vice President...

Exo® Announces Samsung Medison Strategic Collaboration and Welcomes Omar Ishrak to its Board

SANTA CLARA, Calif.--(BUSINESS WIRE)--Exo® announces a strategic collaboration with Samsung Medison and welcomes Omar Ishrak to its Board....
Back to Newsroom